Skip to site menu Skip to page content

Daily Newsletter

13 November 2023

Daily Newsletter

13 November 2023

Ocugen doses first patient in Stargardt disease study

The trial will assess the safety of unilateral subretinal administration of OCU410ST in patients with Stargardt disease.

RanjithKumar Dharma November 13 2023

Ocugen has dosed the first patient in its Phase I/II GARDian clinical study of OCU410ST (AAV5-hRORA) for Stargardt disease.

OCU410ST leverages an AAV delivery platform for the retinal delivery of the RAR Related Orphan Receptor A (RORA) gene.

The trial is designed to assess the safety and efficacy of the modifier gene therapy, OCU410ST, for the rare genetically inherited disease that directly affects the retina, causing slow progressive vision loss in both adults and children.

Designed to be conducted in two phases, the study will evaluate the safety of OCU410ST's unilateral subretinal administration in patients with Stargardt disease.

Phase I is an open-label, multicentre and dose-ranging study, while Phase II is an outcome accessor-blinded, dose-expansion and randomised trial involving paediatric and adult subjects.

The Phase II portion will randomise the subjects in a 1:1:1 ratio to either one of two dose groups of OCU410ST or to an untreated control group.

Ocugen chairman, CEO and co-founder Dr Shankar Musunuri said: “There is a significant unmet medical need for the approximate 35,000 patients in the US living with Stargardt disease.

“It is critical to our mission to develop innovative treatments for inherited retinal diseases and this milestone is an important step in bringing our novel modifier gene therapies to people who desperately need them.”

OCU410ST utilises RORA for regulating pathway links to Stargardt disease such as oxidative stress, complement formation, lipofuscin formation, inflammation, and cell survival networks.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close